Molnupiravir: A new candidate for COVID‐19 treatment. Issue 1 (30th December 2021)

• Record Type: Journal Article
• Authors: Pourkarim, Fariba; Pourtaghi‐Anvarian, Samira; Rezaee, Haleh
• Is Part Of: Pharmacology research & perspectives. Volume 10:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12-30
• Subjects: antiviral drugs -- COVID‐19 treatment -- EIDD‐2801 -- MK‐4482 -- molnupiravir -- novel coronavirus disease 2019; Pharmacology -- Periodicals; Drug development -- Periodicals; 615.105
• DOI: 10.1002/prp2.909
• Languages: English
• ISSNs: 2052-1707

Abstract

Abstract: The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19. Molnupiravir is an antiviral drug with anti‐RNA polymerase activity and currently is under investigation for the treatment of patients with COVID‐19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID‐19 patients. Abstract : Molnupiravir in COVID‐19.